文献速递糖尿病垂体与肾上腺疾病

1型糖尿病是自身免疫性多内分泌病的主要费用驱动因素

Type I Diabetes is the Main Cost Driver in Autoimmune Polyendocrinopathy.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该横断面疾病成本研究纳入146例连续未选择的自身免疫性多内分泌病(AP)患者,通过12个月回顾性访谈估算直接与间接成本。

要点

  • AP患者中T1D患病率为76%,其年均直接成本为€1851,无T1D者为€671。
  • 调整合并自身免疫病后,T1D额外增加直接成本€1209(95%CI €1026-1393,P<0.0001)。
  • T1D预测AP患者的总成本、直接成本、药物成本及糖尿病设备成本(均P<0.001)。

核心结论

  • 自身免疫性多内分泌病具有显著的公共卫生社会经济相关性,1型糖尿病是其主要费用驱动因素。

研究设计与样本

  • 横断面疾病成本研究,在学术三级转诊中心纳入146例连续、未选择的AP患者,通过12个月回顾性访谈收集社会经济数据,并应用人力资本法(HCA)和摩擦成本法(FCA)估算成本。

主要发现

  • 合并T1D的AP患者年均直接成本为€1851,无T1D者为€671;调整合并自身免疫病后,T1D额外增加直接成本€1209(95%CI €1026-1393,P<0.0001)。
  • 合并T1D的AP患者病假成本分别比无T1D者高70%(FCA)和43%(HCA)。
  • 多回归分析中,T1D预测总成本、直接成本、药物成本及糖尿病设备成本(均P<0.001)。
  • 总体而言,合并T1D的AP患者比无T1D者费用高54%(FCA)。

临床怎么用

  • 在内分泌科评估AP患者时,应关注T1D这一主要费用驱动因素,优化其管理可能减轻整体疾病负担。

局限性

  • 本研究为单中心横断面设计,成本估算基于患者回顾性访谈,可能存在回忆偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Autoimmune polyendocrinopathy (AP), a chronic complex orphan disease, encompasses at least two autoimmune-induced endocrine diseases. OBJECTIVE: To estimate for the first time total, indirect and direct costs for patients with AP, as well as cost drivers. DESIGN: Cross-sectional cost of illness study. SETTING: Academic tertiary referral center for AP. PATIENTS: 146 consecutive, unselected AP patients. INTERVENTION: Interviews pertaining to patients' socioeconomic situation covered a recall period of 12 months. Both the human capital (HCA) and the friction cost approaches (FCAs) were applied as estimation methods. MAIN OUTCOME MEASURES: Direct and indirect annual costs, and sick leave and medication costs. RESULTS: AP markedly impacts healthcare expenses. Mean overall costs of AP in Germany ranged from €5 971 090 to €29 848 187 per year (HCA). Mean indirect costs ranged from €3 388 284 to €16 937 298 per year (HCA) while mean direct costs ranged from €2 582 247 to €12 908 095/year. Mean direct costs per year were €1851 in AP patients with type 1 diabetes (T1D, 76%) and €671 without T1D, which amounts to additional direct costs of €1209 for T1D when adjusting for concomitant autoimmune disease (95% CI = €1026-1393, P < 0.0001). Sick leave cost estimates for AP patients with T1D exceeded those without T1D by 70% (FCA) and 43% (HCA), respectively. In multiple regression analyses, T1D predicted total and direct costs, medication costs and costs for diabetic devices (all P < 0.001). Overall, AP patients with T1D were 54% (FCA) more expensive than those without T1D. CONCLUSIONS: Public health socioeconomic relevance of AP was demonstrated, with T1D as main cost driver.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Radermacher LK, Ponto K, Merkesdal S, et al. Type I Diabetes is the Main Cost Driver in Autoimmune Polyendocrinopathy. J Clin Endocrinol Metab. 2020. PMID: 31529067. doi:10.1210/clinem/dgz021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。